On Invalid Date, Aim Immunotech (NYSEMKT: AIM) reported Q2 2023 earnings per share (EPS) of -$0.10, up 0% year over year. Total Aim Immunotech earnings for the quarter were -$4.91 million. In the same quarter last year, Aim Immunotech's earnings per share (EPS) was -$0.10.
As of Q3 2023, Aim Immunotech's earnings has grown year over year. Aim Immunotech's earnings in the past year totalled -$19.34 million.
What is AIM's earnings date?
Aim Immunotech's earnings date is Invalid Date. Add AIM to your watchlist to be reminded of AIM's next earnings announcement.
What was AIM's revenue last quarter?
On Invalid Date, Aim Immunotech (NYSEMKT: AIM) reported Q2 2023 revenue of $42.00 thousand up 40% year over year. In the same quarter last year, Aim Immunotech's revenue was $30.00 thousand.
What was AIM's revenue growth in the past year?
As of Q3 2023, Aim Immunotech's revenue has grown 15.07% year over year. This is 86.1 percentage points lower than the US Biotechnology industry revenue growth rate of 101.17%. Aim Immunotech's revenue in the past year totalled $168.00 thousand.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.